Author:
Cárdenas-Robledo Simón,Arenas-Vargas Laura Estefanía,Arenas Rubén Darío,Gaspar-Toro Jorge Mario,Muñoz-Rosero Ángela María,Tafur-Borrero Aranza Helena,Marín-Medina Daniel Stiven,Acosta-Fajardo Hernan Andrés,Guío-Sánchez Claudia,López-Reyes Lorena
Abstract
Abstract
Background
Effective interventions for Multiple Sclerosis require timely treatment optimization which usually involves switching disease modifying therapies. The patterns of prescription and the reasons for changing treatment in people with MS, especially in low prevalence populations, are unknown.
Objectives
To describe the persistence, reasons of DMT switches and prescription patterns in a cohort of Colombian people with MS.
Methods
We conducted a retrospective observational study including patients with confirmed MS with at least one visit at our centre. We estimated the overall incidence rate of medication changes and assessed the persistence on medication with Kaplan–Meier survival estimates for individual medications and according to efficacy and mode of administration. The factors associated with changing medications were assessed using adjusted Cox proportional-hazards models. The reasons for switching medication changes were described, and the prescription patterns were assessed using network analysis, with measures of centrality.
Results
Seven hundred one patients with MS were included. Mean age was 44.3 years, and 67.9% were female. Mean disease duration was 11.3 years and 84.5% had relapsing MS at onset, with median EDSS of 1.0. Treatment was started in 659 (94%) of the patients after a mean of 3 years after MS symptom onset. Among them, 39.5% maintained their initial DMT, 29.9% experienced a single DMT change, while 18.7% went through two, and 11.9% had three or more DMT changes until the final follow-up. The total number of treatment modifications reached 720, resulting in an incidence rate of 1.09 (95% confidence interval: 1.01–1.17) per patient per year The median time to change after the first DMT was 3.75 years, and was not different according to the mode of administration or efficacy classification. The main reasons for changing DMT were MS activity (relapses, 56.7%; MRI activity, 18.6%), followed by non-serious adverse events (15.3%) and disability (11.1%). Younger age at MS onset, care under our centre and insurer status were the main determinants of treatment change. Network analysis showed that interferons and fingolimod were the most influential DMTs.
Conclusions
A majority of patients switch medications, mostly due to disease activity, and in association with age and insurer status.
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA, et al. Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS. Mult Scler J. 2020;26:1816–21.
2. Tintore M, Vidal-Jordana A, Sastre-Garriga J. Treatment of multiple sclerosis — success from bench to bedside. Nat Rev Neurol. 2019;15:53–8.
3. Dobson R, Giovannoni G. Multiple sclerosis – a review. Eur J Neurol. 2019;26:27–40.
4. Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15:287–300.
5. Gross RH, Corboy JR. Monitoring, switching, and stopping multiple sclerosis disease-modifying therapies. Continuum (Minneap Minn). 2019;25:715–35.